Company Overview
ClearPoint Neuro, Inc. operates as a commercial-stage medical device company dedicated to the development and commercialization of specialized platforms designed for minimally invasive surgical procedures within the human brain in the United States. The firm functions within the healthcare sector, specifically targeting the medical devices industry, which implies a focus on advanced technology and regulatory compliance for life-critical equipment. The company currently maintains a market capitalization of $282.31M and employs 172 individuals to support its operations and research initiatives. With a trailing twelve-month revenue of $36.97M, the company demonstrates a mid-sized enterprise profile that suggests it has moved past initial commercialization phases but remains in a growth-oriented position relative to its peers.
Financial Health
ClearPoint Neuro, Inc. reported a trailing twelve-month revenue of $36.97M, yet it recorded a net income of $-25,540,000 and an EBITDA of $-21,481,000 for the same period. The significant disparity between the positive revenue of $36.97M and the substantial negative net income indicates a cost structure where expenses, likely driven by research and development or commercialization costs, significantly outpace gross profits at this stage of operation. The company generated negative free cash flow of $-9,635,000, which reflects a current state of cash consumption rather than generation, suggesting that the firm is utilizing its cash reserves to fund growth initiatives or cover operational deficits. The gross margin stands at 61.4%, indicating that the company retains a healthy portion of revenue from its core device sales before accounting for operating expenses. Conversely, the operating margin is negative at -50.4%, and the profit margin is -69.1%, highlighting that high operating expenditures are eroding profitability despite strong gross margins. On the balance sheet, the company holds $45.92M in cash against $58.23M in total debt, resulting in a debt-to-equity ratio of 207.82, which characterizes the capital structure as highly leveraged. The current ratio is listed at 5.91, a figure that suggests the company possesses a robust capacity to meet its short-term liabilities with its current assets. Furthermore, the return on equity is -95.6% and the return on assets is -20.4%, metrics that reveal that the management team is currently generating negative returns on the capital deployed by shareholders and asset holders.
Valuation Assessment
The valuation metrics for ClearPoint Neuro, Inc. show a P/E ratio (TTM) of N/A due to negative earnings, while the forward P/E is listed at -11.64. The absence of a trailing P/E and the negative forward P/E imply that the market is pricing in a future trajectory where earnings are expected to turn positive or that valuation is currently based on non-traditional multiples. The price-to-book ratio is 9.95, which indicates that the market is valuing the company at a significant premium over its net book value, often seen in biotech and medtech firms with intangible assets or high growth potential. Alternative valuation metrics such as the price-to-sales ratio of 7.64 and an EV/EBITDA of -13.68 provide further context, suggesting that investors are assessing the firm based on revenue multiple expansion rather than current profitability. The stock has a 52-week high of $30.10 and a 52-week low of $8.63, defining the recent trading volatility range for the security. The beta value is 1.07, which indicates that the stock price tends to be slightly more volatile than the broader market, moving with a sensitivity that exceeds the general market index by 7%.
Growth & Income
ClearPoint Neuro, Inc. demonstrated a revenue growth of 34.0% year-over-year, whereas the earnings growth is listed as N/A due to the company's current net losses. The divergence between strong revenue expansion and negative earnings growth implies that the top-line growth is not yet translating into bottom-line profitability, a common characteristic of commercial-stage medical device companies investing heavily in expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all of its earnings to fund operations and reinvest into product development rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue scaling funded by internal cash reserves and external capital markets, with no current cash return to investors via dividends.